Prevalence and Significance of HIV-1 Drug Resistance Mutations among Patients on Antiretroviral Therapy with Detectable Low-Level Viremia | Zendy

Jonathan Z. Li | Zendy; Sébastien Gallien | Zendy; Tri D. | Zendy; Jeffrey N. Martin | Zendy; Steven G. Deeks | Zendy; Daniel R. Kuritzkes | Zendy; Hiroyu Hatano | Zendy

Open Access

Prevalence and Significance of HIV-1 Drug Resistance Mutations among Patients on Antiretroviral Therapy with Detectable Low-Level Viremia

Author(s) -

Jonathan Z. Li,

Sébastien Gallien,

Tri D.,

Jeffrey N. Martin,

Steven G. Deeks,

Daniel R. Kuritzkes,

Hiroyu Hatano

Publication year - 2012

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01217-12

Subject(s) - viremia , viral load , drug resistance , medicine , virology , human immunodeficiency virus (hiv) , antiretroviral therapy , hiv drug resistance , antiretroviral drug , immunology , biology , genetics

HIV-1 resistance testing was performed in 47 antiretroviral (ARV)-treated subjects with low-level viremia (LLV) of <1,000 copies/ml. The median viral load was 267 copies/ml. In those with ≥2 LLV episodes, 44% accumulated additional resistance mutations. Fewer active ARVs and longer elapsed time were associated with an increased risk of resistance accumulation after controlling for adherence and viral load. Virologic failure followed 16% of LLV time points. Strategies for early intervention after LLV episodes should be further studied.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research